HIKAL LIMITED (HIKAL) financials
HIKAL LIMITED (HIKAL) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection f…
- Market Cap: ₹2,679Cr.
- Current Price: ₹217
- Stock P/E: 62.7
- ROE: 2.22%
- ROCE: 3.51%
- Book Value: ₹97.2
- Dividend Yield: 0.28%
- 52W High / Low: ₹261/146
In Jun 2026, HIKAL LIMITED (HIKAL) reported sales ₹402.80 Cr and net profit ₹-7.50 Cr.
Annual TTM: sales ₹1,735 Cr, net profit ₹-34 Cr.
Shareholding: Promoters 68.85% (Sep 2026), FIIs 1.28% (Sep 2026), DIIs 5.31% (Sep 2026), Public 24.57% (Sep 2026), No. of Shareholders 74,784% (Sep 2026).
| Category | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 452.90 | 447.70 | 552.40 | 380.40 | 318.50 | 494.30 | 519.40 | 402.80 |
| Expenses | 378.20 | 375.50 | 428.90 | 355.60 | 311.10 | 411.60 | 413.80 | 365.90 |
| Operating Profit | 74.70 | 72.20 | 123.50 | 24.80 | 7.40 | 82.70 | 105.60 | 36.90 |
| OPM % | 16.49% | 16.13% | 22.36% | 6.52% | 2.32% | 16.73% | 20.33% | 9.16% |
| Other Income | 0.40 | 3.60 | 0.50 | 1.00 | 1.90 | -35.20 | -40.50 | 10.70 |
| Interest | 18.80 | 18.70 | 17.90 | 17.10 | 14.90 | 15.50 | 14.60 | 14.90 |
| Depreciation | 31.70 | 33.20 | 37.70 | 39.40 | 41.20 | 41.20 | 42.00 | 42.70 |
| Profit before tax | 24.60 | 23.90 | 68.40 | -30.70 | -46.80 | -9.20 | 8.50 | -10.00 |
| Tax % | 26.42% | 27.62% | 26.46% | -26.06% | -25.85% | -35.87% | -71.76% | -25.00% |
| Net Profit | 18.10 | 17.30 | 50.30 | -22.70 | -34.70 | -5.90 | 14.60 | -7.50 |
| EPS in Rs | 1.47 | 1.40 | 4.08 | -1.84 | -2.81 | -0.48 | 1.18 | -0.61 |
| Raw PDF | — | — | — | — | — | — | — | — |
| Category | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,507 | 1,720 | 1,943 | 2,023 | 1,785 | 1,860 | 1,713 | 1,735 |
| Expenses | 1,234 | 1,398 | 1,602 | 1,765 | 1,518 | 1,531 | 1,492 | 1,502 |
| Operating Profit | 273 | 323 | 341 | 258 | 267 | 328 | 220 | 233 |
| OPM % | 18% | 19% | 18% | 13% | 15% | 18% | 13% | 13% |
| Other Income | -12 | 5 | 5 | 5 | 2 | 5 | -73 | -63 |
| Interest | 52 | 36 | 31 | 48 | 56 | 75 | 62 | 60 |
| Depreciation | 82 | 85 | 96 | 109 | 118 | 134 | 164 | 167 |
| Profit before tax | 127 | 206 | 219 | 105 | 95 | 124 | -78 | -58 |
| Tax % | 33% | 36% | 27% | 26% | 27% | 27% | -38% | — |
| Net Profit | 84 | 133 | 161 | 78 | 70 | 91 | -49 | -34 |
| EPS in Rs | 6.85 | 10.80 | 13.02 | 6.36 | 5.64 | 7.37 | -3.95 | -2.72 |
| Dividend Payout % | 18% | 19% | 12% | 19% | 21% | 19% | -15% | — |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| Reserves | 732 | 792 | 909 | 1,043 | 1,109 | 1,163 | 1,238 | 1,174 |
| Borrowings | 661 | 646 | 610 | 675 | 748 | 818 | 765 | 684 |
| Other Liabilities | 268 | 306 | 370 | 470 | 504 | 482 | 502 | 483 |
| Total Liabilities | 1,686 | 1,768 | 1,913 | 2,213 | 2,385 | 2,487 | 2,529 | 2,365 |
| Fixed Assets | 713 | 735 | 713 | 879 | 948 | 1,071 | 1,364 | 1,333 |
| CWIP | 79 | 161 | 254 | 295 | 412 | 414 | 121 | 94 |
| Investments | 1 | 1 | 1 | 11 | 5 | 5 | 10 | 10 |
| Other Assets | 893 | 871 | 946 | 1,028 | 1,020 | 997 | 1,034 | 928 |
| Total Assets | 1,686 | 1,768 | 1,913 | 2,213 | 2,385 | 2,487 | 2,529 | 2,365 |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 186 | 285 | 229 | 294 | 315 | 187 | 280 | 302 |
| Cash from Investing Activity | -125 | -164 | -156 | -284 | -292 | -174 | -136 | -145 |
| Cash from Financing Activity | -55 | -101 | -97 | -6 | -8 | -27 | -144 | -160 |
| Net Cash Flow | 6 | 20 | -24 | 4 | 15 | -14 | 0 | -3 |
| Free Cash Flow | 57 | 127 | 71 | 21 | 13 | -17 | 144 | 154 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 73% | 113% | 85% | 107% | 134% | 81% | 94% | 144% |
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% |
| FIIs | 6.06% | 5.70% | 5.35% | 4.23% | 2.31% | 1.44% | 0.98% | 1.28% |
| DIIs | 3.48% | 3.80% | 4.03% | 5.15% | 7.05% | 7.20% | 7.23% | 5.31% |
| Public | 21.61% | 21.65% | 21.76% | 21.75% | 21.78% | 22.51% | 22.92% | 24.57% |
| No. of Shareholders | 71,801 | 68,907 | 71,391 | 73,404 | 74,117 | 74,270 | 73,527 | 74,784 |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 82 | 103 | 82 | 80 | 113 | 103 | 94 |
| Inventory Days | 156 | 147 | 107 | 121 | 104 | 134 | 146 | 172 |
| Days Payable | 68 | 95 | 92 | 91 | 103 | 123 | 133 | 128 |
| Cash Conversion Cycle | 168 | 135 | 118 | 112 | 81 | 124 | 116 | 138 |
| Working Capital Days | 45 | 28 | 39 | 26 | 39 | 39 | 37 | 41 |
| ROCE % | 15% | 14% | 16% | 15% | 8% | 8% | 10% | 4% |
Hikal Limited
₹2,679Cr.
₹217
₹261/146
62.7
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad {Maharashtra). The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal's R & D facilities are located in Pune.[1]
Quarterly results
Profit & loss
Shareholding trend
Balance sheet
Cash flows
Key ratios
Frequently asked questions
What is the market cap of HIKAL LIMITED (HIKAL)?
The reported market capitalisation for HIKAL LIMITED (HIKAL) is ₹2,679Cr. on Fincrux. Figures may update with market data and filings.
What is the current share price of HIKAL?
The current price shown for HIKAL LIMITED (HIKAL) on Fincrux is ₹217 with a 52-week high/low of ₹261/146.
What is the P/E ratio of HIKAL LIMITED (HIKAL)?
The stock P/E for HIKAL LIMITED (HIKAL) is 62.7 on Fincrux, with ROE at 2.22% and ROCE at 3.51%.
What were HIKAL latest quarterly results?
For Jun 2026, HIKAL LIMITED (HIKAL) reported sales ₹402.80 Cr and net profit ₹-7.50 Cr (figures in ₹ crore unless noted).
What are HIKAL annual sales and net profit?
For TTM, HIKAL LIMITED (HIKAL) shows sales of ₹1,735 Cr and net profit of ₹-34 Cr on the Fincrux profit & loss statement.
Who owns HIKAL LIMITED (HIKAL)?
Latest shareholding for HIKAL LIMITED (HIKAL) on Fincrux: Promoters 68.85% (Sep 2026), FIIs 1.28% (Sep 2026), DIIs 5.31% (Sep 2026), Public 24.57% (Sep 2026), No. of Shareholders 74,784% (Sep 2026).
Where can I find HIKAL LIMITED (HIKAL) financials?
HIKAL LIMITED (HIKAL) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.
Does Fincrux show HIKAL balance sheet and cash flow?
Yes. The HIKAL LIMITED (HIKAL) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.